甲强龙治疗重型药物性肝损伤合并银屑病1例报告

卢朝秀; 郭鑫; 越东杰; 吴飞飞

doi:10.3969/j.issn.1001-5256.2020.03.037

甲强龙治疗重型药物性肝损伤合并银屑病1例报告

DOI: 10.3969/j.issn.1001-5256.2020.03.037

1. 长治医学院
2. 长治医学院附属和平医院

详细信息

中图分类号: R575;R758.63
计量
- 文章访问数: 812
- HTML全文浏览量: 7
- PDF下载量: 173
- 被引次数: 0
出版历程
- 出版日期: 2020-03-20

Therapeutic effect of methylprednisolone in treatment of severe drug-induced liver injury with psoriasis: A case report

Changzhi Medical College

摘要

摘要: <正>1病例资料患者男性,31岁,以"全身乏力20余天,尿黄半月,皮肤、巩膜黄染1周"于2018年3月19日住院。患者既往有"银屑病"13余年,无高血压、糖尿病病史;无吸烟、饮酒史;无家族遗传倾向性疾病。于2009年6月至某中医就诊,给予服用"中药"(用药成分不详)治疗3个月,治疗期间出现腹泻,7～8次/d,黄稀便,无腹痛、皮肤黄染、恶心、呕吐等不适,治疗后皮损逐渐缩小接近正
- 药物性肝损伤 /
- 银屑病 /
- 中草药 /
- 糖皮质激素类
- drug-induced liver injury /
- psoriasis /
- drugs,Chinese herbal /
- glucocorticoids

HTML全文

参考文献(13)

[1] Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组．药物性肝损伤诊治指南[J]．临床肝胆病杂志，2015,31(11):1752-1769.

[2] WANG SW,XIE W. Research progress on high mobility group protein box 1 in drug induced liver injury[J/CD]. Chin J Liver Dis(Electronic Edition),2018,10(2):1-5.(in Chinese)王世伟，谢雯．高迁移率族蛋白-1在药物性肝损伤中的研究进展[J/CD]．中国肝脏病杂志(电子版)，2018,10(2):1-5.

[3] MA YB,LI YL,ZHANG J. Influence of ursodeoxycholic acid combined with S-adenosine methionine on liver function,Nrf2 antioxidant and inflammatory response in patients with drug-induced liver injury[J]. J Clin Exp Med,2018,17(24):2606-2610.(in Chinese)马雅斌，李语玲，张津．熊去氧胆酸联合S-腺苷蛋氨酸对药物性肝损伤患者肝功能、Nrf2抗氧化、炎症反应的影响[J]．临床和实验医学杂志，2018,17(24):2606-2610.

[4] HU PF,WANG PQ,CHEN H,et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury[J]. J Dig Dis,2016,17(9):618-627.

[5] FONTANA RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives[J]. Gastroenterology,2014,146(4):914-928.

[6] KLEINER DE,CHALASANI NP,LEE WM,et al. Hepatic histological findings in suspected drug-induced liver injury:Systematic evaluation and clinical associations[J]. Hepatology,2014,59(2):661-670.

[7] ZHANG YG,ZHAO SX,LI WC,et al. Treatment response of glucocorticoid in severe drug-induced liver injury[J]. Liver,2017,22(3):214-218.

[8] DUPIRE G,DROITCOURT C,HUGHES C. Antistreptococcal interventions for guttate and chronic plaque psoriasis[J]. Cochrane Database Syst Rev,2019,3:CD011571.

[9] SARKAR MK,KAPLAN N,TSOI LC,et al. Endogenous glucocorticoid deficiency in psoriasis promotes inflammation and abnormal differentiation[J]. J Invest Dermatol,2017,137(7):1474-1483.

[10] NICKOLOFF BJ,NESTLE FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities[J]. J Clin Invest,2004,113(12):1664-1675.

[11] Specialized Committee on Autoimmunol Diseases,Chinese Medical Doctor Association Dermatology Branch. Expert consensus on the treatment of immune-related dermatosis with glucocorticoid(2018)[J]. Chin J Clin Immunol Allergy,2018,12(1):1-7.(in Chinese)中国医师协会皮肤科医师分会自身免疫性疾病亚专业委员会．糖皮质激素治疗免疫相关性皮肤病专家共识(2018年)[J]．中华临床免疫和变态反应杂志，2018,12(1):1-7.

[12] Ministry of Health. Guidelines for clinical application of glucocorticoids(excerpt)[J]. ADRJ,2011,13(1):40-44.(in Chinese)卫生部．糖皮质激素类药物临床应用指导原则(节选)[J]．药物不良反应杂志，2011,13(1):40-44.

[13] LEVINE D,GOTTLIEB A. Evaluation and management of psoriasis:An internist's guide[J]. Med Clin North Am,2009,93(6):1291-1303.

施引文献

资源附件(0)

访问统计